Group 1 - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 14,000 shares on November 13, 2025 [1] - Over the past 5 trading days, there has been a cumulative net reduction of 192,000 shares by southbound funds [1] - In the last 20 trading days, southbound funds have reduced their holdings for 20 days, totaling a net reduction of 1.733 million shares [1] Group 2 - As of now, southbound funds hold 110 million shares of HeartCare Medical-B, accounting for 4.55% of the company's total issued ordinary shares [1] - The company specializes in providing comprehensive medical solutions for structural heart disease, focusing on transcatheter and surgical solutions [2] - HeartCare Medical's product pipeline includes TAVI series products, AnchorMan left atrial appendage occluder products, transcatheter mitral valve products, transcatheter tricuspid valve products, and surgical support products [2]

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 28,000 shares on November 4, 2025, marking a total net reduction of 596,000 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have decreased their holdings by a total of 1,934,000 shares, indicating a consistent trend of selling [1] - As of now, southbound funds hold 110 million shares of HeartCare Medical-B, which represents 4.56% of the company's total issued ordinary shares [1] Trading Data Summary - On November 4, 2025, total shares held were 110 million, with a decrease of 28,000 shares, reflecting a change of -0.03% [2] - On November 3, 2025, total shares held remained at 110 million, with a decrease of 86,000 shares, reflecting a change of -0.08% [2] - On October 24, 2025, total shares held were 110 million, with a decrease of 109,000 shares, reflecting a change of -0.10% [2] - On October 21, 2025, total shares held were 111 million, with a decrease of 273,000 shares, reflecting a change of -0.25% [2] - On October 16, 2025, total shares held were 111 million, with a decrease of 100,000 shares, reflecting a change of -0.09% [2] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical support products [2] - The company operates in both domestic and international markets [2]

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 191,000 shares on October 15, 2025, marking a total net reduction of 856,000 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have consistently reduced their holdings, totaling a net decrease of 1,461,000 shares [1] - As of now, southbound funds hold 111 million shares of HeartCare Medical-B, representing 4.58% of the company's total issued ordinary shares [1] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical accessory products [2] - The company operates in both domestic and international markets [2]

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 223,000 shares on October 13, 2025, marking a continuous trend of selling over the past trading days [1] - Over the last 5 trading days, there has been a total net reduction of 724,000 shares, while in the last 20 trading days, the cumulative net reduction reached 1,385,000 shares [1] - As of now, southbound funds hold 111 million shares of HeartCare Medical-B, which represents 4.59% of the company's total issued ordinary shares [1] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical support products [2] - The company operates in both domestic and international markets [2]

Group 1 - The core transaction involves MicroPort Cardio Flow CRM Limited acquiring CRM Cayman through a merger agreement, with CRM Cayman becoming a wholly-owned subsidiary of MicroPort Cardio Flow upon completion [1][2] - The merger will involve the issuance of new shares at a price of HKD 1.35 per share to CRM Cayman shareholders, with a pre-transaction equity value of CRM Cayman estimated at USD 680 million [1][2] - The merger is strategically aligned with MicroPort Cardio Flow's business development, aiming to establish a global cardiac product platform and enhance its product offerings and capabilities in structural heart disease and arrhythmia management [2] Group 2 - CRM Cayman and its subsidiaries focus on arrhythmia management solutions, providing devices to monitor heart conditions and deliver treatments [2] - MicroPort Cardio Flow specializes in innovative transcatheter solutions for structural heart disease, with products including valve products and left atrial appendage occluders [2] - The merger is expected to create complementary synergies that will diversify and expand MicroPort Cardio Flow's existing business, particularly in research and development, manufacturing, distribution channels, and market expansion [2]

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 77,000 shares on September 18, 2025, marking a continuous trend of selling over the past trading days [1] - Over the last 5 trading days, there has been a total net reduction of 215,000 shares, and in the last 20 trading days, the cumulative net reduction reached 2.876 million shares [1] - As of now, southbound funds hold 112 million shares of HeartCare Medical-B, which accounts for 4.63% of the company's total issued ordinary shares [1] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical support products, with operations in both domestic and international markets [2]